Artemether: A New Therapeutic Strategy in Experimental Rheumatoid Arthritis

REFERENCES

• Efferth T. Mechanistic perspectives for 1,2,4-trioxanes in anti-cancer therapy. Drug Resist. Updat. 2005; 8: 85–97, [CSA]
   PubMed Web of Science ®Google Scholar
• Tan R.X., Zheng W.F., Tang H.Q. Biologically active substances from the genus Artemisia. Planta Med. 1998; 64: 295–302, [CSA]
   PubMed Web of Science ®Google Scholar
• Van der Meersch H. Review of the use of artemisinin and its derivatives in the treatment of malaria. J. Pharm. Belg. 2005; 60: 23–29, [CSA]
   PubMedGoogle Scholar
• Haynes R.K., Chan H.W., Ho W.Y., Ko C.K., Gerena L., Kyle D.E., Peters W., Robinson B.L. Convenient access both to highly antimalaria-active 10-arylaminoartemisinins, and to 10-alkyl ethers including artemether, arteether, and artelinate. Chembiochem. 2005; 6: 659–667, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Efferth T., Marschall M., Wang X., Huong S.M., Hauber I., Olbrich A. Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegaloviruses. J. Mol. Med. 2002; 80: 233–242, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mahmoud M.R., Botros S.S. Artemether as adjuvant therapy to praziquantel in murine Egyptian schistosomiasis mansoni. J. Parasitol. 2005; 91: 175–178, [CSA]
   PubMed Web of Science ®Google Scholar
• Efferth T., Olbrich A., Bauer R. mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochem. Pharmacol. 2002; 64: 617–623, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985; 228: 1049–1055, [CSA]
   PubMed Web of Science ®Google Scholar
• Butler A.R., Wu Y.L. Artemisinin (qinghaosu)—a new type of antimalarial drug. Chem. Soc. Rev. 1992; 21: 85–90, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Price R., van Vugt M., Nosten F., Luxemburger C., Brockman A., Phaipun L., Chongsuphajaisiddhi T., White N. Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria. Am. J. Trop. Med. Hyg. 1998; 59: 883–888, [CSA]
   PubMed Web of Science ®Google Scholar
• Ribeiro I.R., Olliaro P. Safety of artemisinin and its derivatives. A review of published and unpublished clinical trials. Med. Trop. 1998; 58: 50–53, [CSA]
   Google Scholar
• De Vries P.J., Dien T.K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52: 818–836, [CSA]
   PubMed Web of Science ®Google Scholar
• Shen W.J., Thiero M. Effects of combined artemether and dihydroartemisinin in treatment of children with falciparum malaria. Zhonghua Er. Ke. Za. Zhi. 2005; 43: 65–66, [CSA]
   PubMedGoogle Scholar
• Sutherland C.J., Ord R., Dunyo S., Jawara M., Drakeley C.J., Alexander N., Coleman R., Pinder M., Walraven G., Targett G.A. Reduction of malaria transmission to anopheles mosquitoes with a six-dose regimen of co-artemether. Plo. S. Med. 2005; 2: e92, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Falade C., Makanga M., Premji Z., Ortmann C.E., Stockmeyer M., de Palacios P.I. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans. R. Soc. Trop. Med. Hyg. 2005; 99: 459–467, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aceng J.R., Byarugaba J.S., Tumwine J.K. Rectal artemether versus intravenous quinine for the treatment of cerebral malaria in children in Uganda: randomised clinical trial. Br. Med. J. 2005; 330: 317–318, [CSA]
   PubMedGoogle Scholar
• Wartenberg M., Wolf S., Budde P., Grunheck F., Acker H., Hescheler J., Wartenberg G., Sauer H. The antimalaria agent artemisinin exerts antiangiogenic effects in mouse embryonic stem cell-derived embryoid bodies. Lab. Invest. 2003; 83: 1647–1655, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• He X.L., Liu Z. Protection of artesunate on activation and injury of vascular endothelial cells induced by lipopolysaccharide. Zhongguo Zhong Xi. Yi. Jie. He. Za. Zhi. 2004; 24: 1110–1113, [CSA]
   PubMedGoogle Scholar
• Kwiatkowski D., Bate C. Inhibition of tumour necrosis factor (TNF) production by antimalarial drugs used in cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 1995; 89: 215–216, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wu G.D., Zhou H.J., Wu X.H. Apoptosis of human umbilical vein endothelial cells induced by artesunate. Vascul. Pharmacol. 2004; 41: 205–212, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chen H.H., Zhou H.J., Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol. Res. 2003; 48: 231–236, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sun X.Z. Experimental study on the immunosuppressive effects of qinghaosu and its derivative. Zhong Xi. Yi. Jie. He. Za. Zhi. 1991; 11: 37–38, [CSA]
   PubMedGoogle Scholar
• Aldieri E., Atragene D., Bergandi L., Riganti C., Costamagna C., Bosia A., Ghigo D. Artemisinin inhibits inducible nitric oxide synthase and nuclear factor NF-κB activation. FEBS Lett 2003; 552: 141–144, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S., Mazzon E., Bevilaqua C., Costantino G., Britti D., Mazzullo G., De Sarro A., Caputi A.P. Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Br. J. Pharmacol. 2000; 131: 1399–1407, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Szabo C., Virag L., Cuzzocrea S., Scott G.S., Hake P., O’Connor M. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthetase. Proc. Natl. Acad. Sci. USA. 1998; 9: 3867–3872, [CSA], [CROSSREF]
   Web of Science ®Google Scholar
• Bremell T., Abdelnour A., Tarkowski A. Histopathological and serological progression of experimental Staphylococcus aureus arthritis. Infect. Immun. 1992; 60: 2976–2985, [CSA]
   PubMed Web of Science ®Google Scholar
• Oliver S.J., Cheng T.P., Banquerigo M.L., Brahn E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell. Immunol. 1995; 166: 196–206, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mirshafiey A., Chitsaz M., Attar M., Mehrabian F., Razavi A.R. Culture filtrate of Cryptococcus neoformans var. gattii (CneF) as a novel anti-inflammatory compound in the treatment of experimental septic arthritis. Scand. J. Immunol. 2000; 52: 278–284, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cuzzocrea S., Costantino G., Mazzon E., Caputi A.P. Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy. Br. J. Pharmacol. 1999; 126: 407–414, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heussen C., Dowdle E.B. Electrophoretic analysis of plasminogen activator in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal. Biochem. 1980; 102: 196–202, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Harris E.D. Rheumatoid arthritis: pathophysiology and implications for therapy. N. Engl. J. Med. 1990; 322: 1277–1289, [CSA]
   PubMed Web of Science ®Google Scholar
• Griffiths M.M., Eichwald E.J., Martin J.H., Smith C.B., DeWitt C.W. Immunogenetic control of experimental type II collagen–induced arthritis. I. Susceptibility and resistance among inbred strains of rats. Arthritis Rheum. 1981; 24: 781–789, [CSA]
   PubMed Web of Science ®Google Scholar
• Larsson P., Kleinau S., Holmdahl R., Klareskog L. Homologous type II collagen–induced arthritis in rats: characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum. 1990; 33: 693–701, [CSA]
   PubMedGoogle Scholar
• Stuart J.M., Townes A.S., Ang A.H. The role of collagen autoimmunity in animals and human diseases. J. Invest. Dermatol. 1982; 79: 1–11, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Clague R.B., Morgan K., Shaw M.J., Holt P.J. Native type II collagen-induced arthritis in the rat. II. Relationship between the humoral immune response to native type II collagen and arthritis. J. Rheumatol. 1980; 7: 775–782, [CSA]
   PubMed Web of Science ®Google Scholar
• Takeshita M., Hinoue H., Furukawa O., Takata I. Initial arthritic lesions induced by immunization with type II collagen in Lewis rats. Exp. Anim. 1995; 44: 63–66, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Takeshita M., Sugita T., Takata I. Pathological evaluation of effect of anti-rheumatic drugs on type II collagen-induced arthritis in Lewis rats. Exp. Anim. 1997; 46: 165–169, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Holmdahl R., Andersson M., Goldschmidt T.J., Gustafsson K., Jansson L., Mo J.A. Type II collagen autoimmunity in animals and provocations leading to arthritis. Immunol. Rev. 1990; 118: 193–232, [CSA]
   PubMed Web of Science ®Google Scholar
• Weinblatt M.E. Rheumatoid arthritis: treat now, not later. Ann. Intern. Med. 1996; 124: 773–774, [CSA]
   PubMed Web of Science ®Google Scholar
• Boey M.L. Treatment strategies in rheumatoid arthritis. Singapore Med. J. 1992; 33: 631–632, [CSA]
   PubMedGoogle Scholar
• Araiza-Casillas R., Cardenas F., Morales Y., Cardiel M.H. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13: 119–124, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wassenberg S., Rau R. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis. J. Rheumatol. 2003; 30: 1891–1892, [CSA]
   PubMed Web of Science ®Google Scholar
• Johnsen V., Forre O., Haga H.J., Kvien T.K., Mikkelsen K., Nordvag B.Y., Rodevand E. Combination therapy in rheumatoid arthritis. Tidsskr. Nor. Laegeforen. 2003; 123: 1511–1513, [CSA]
   PubMedGoogle Scholar
• Carmichael S.J., Charles B., Tett S.E. Population pharmacokinetics of hydroxychloroquine in patients with rheumatoid arthritis. Ther. Drug Monit. 2003; 25: 671–681, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Carmichael S.J., Beal J., Day R.O., Tett S.E. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J. Rheumatol. 2002; 29: 2077–2083, [CSA]
   PubMed Web of Science ®Google Scholar
• Mauri C., Williams R.O., Walmsley M., Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur. J. Immunol. 1996; 26: 1511–1518, [CSA]
   PubMed Web of Science ®Google Scholar
• Mussener A., Klareskog L., Lorentzen J.C., Kleinau S. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen and oil-induced arthritis. Scand. J. Immunol. 1995; 42: 128–134, [CSA]
   PubMed Web of Science ®Google Scholar
• Ialenti A., Moncada S., Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br. J. Pharmacol. 1993; 110: 701–706, [CSA]
   PubMed Web of Science ®Google Scholar
• Salvemini D., Wang Z.Q., Wyatt P.S., Bourdon D.M., Marino M.H., Manning P.T., Currie M.G. Nitric oxide: a key mediator in the early and late phase of carrageenan-induced rat paw inflammation. Br. J. Pharmacol. 1996; 118: 829–838, [CSA]
   PubMed Web of Science ®Google Scholar
• Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., Stuart J.M. Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 1992; 148: 2103–2108, [CSA]
   PubMed Web of Science ®Google Scholar
• Mattsson L., Lorentzen J.C., Svelander L., Bucht A., Nyman U., Klareskog L., Larsson P. Immunization with alum-collagen II complex suppresses the development of collagen-induced arthritis in rats by deviating the immune response. Scand. J. Immunol. 1997; 46: 619–624, [CSA]
   PubMed Web of Science ®Google Scholar
• Hitchon C.A., Danning C.L., Illei G.G., EI-Gabalawy H.S., Boumpas D.T. Gelatinase expression and activity in the synovium and skin of patients with erosive psoriatic arthritis. J. Rheumatol. 2002; 29: 107–117, [CSA]
   PubMed Web of Science ®Google Scholar
• Jackson C.J., Arkell J., Guyen M. Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann. Rheum. Dis. 1998; 57: 158–161, [CSA]
   PubMed Web of Science ®Google Scholar
• Dell’Eva R., Pfeffer U., Vene R., Anfosso L., Forlani A., Albini A., Efferth T. Inhibition of angiogenesis in vivo and growth of Kaposi’s sarcoma xeno grafttumors by the anti-malarial artesunate. Biochem. Pharmacol. 2004; 68: 2359–2366, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J. Immunol. Methods. 1986; 95: 99–105, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Firestein G.S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis: passive responders or transformed aggressors?. Arthritis Rheum 1996; 39: 1781–1790, [CSA]
   PubMed Web of Science ®Google Scholar
• Bucala R., Ritchlin C., Winchester R., Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J. Exp. Med. 1991; 173: 569–574, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cho M.L., Kim W.U., Min S.Y., Min D.J., Min J.K., Lee S.H., Park S.H., Cho C.S., Kim H.Y. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor aproduction by rheumatoid synoviocytes. Arthritis Rheum 2002; 6: 2–51, [CSA]
   Google Scholar